Clin Exp Reprod Med.  2013 Jun;40(2):100-105. 10.5653/cerm.2013.40.2.100.

Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome

Affiliations
  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. ymchoi@snu.ac.kr
  • 2Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, Korea.
  • 3The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.
  • 4Seoul National University Hospital Healthcare System Gangnam Center, Seoul National University College of Medicine, Seoul, Korea.
  • 5Maria Fertility Hospital, Seoul, Korea.

Abstract


OBJECTIVE
The aim of this study was to investigate the effect of insulin sensitizing agents on hormonal and metabolic parameters as well as menstrual patterns in women with polycystic ovary syndrome (PCOS).
METHODS
One hundred and twenty-three patients with PCOS were included. Metformin was administered to patients at 1,500 mg or 1,700 mg daily for 3 months. If the patients had no improvement of the menstrual cycle or metformin-related adverse effects developed, the patients changed medication to a daily dose of either 15 mg pioglitazone or up to 45 mg. Then resumption of a regular menstrual cycle or recovery of ovulation was evaluated. Hormonal and metabolic profiles were compared between the response and non-response group to insulin sensitizing agents.
RESULTS
One hundred and five patients with PCOS were treated with metformin for 3 months. Forty-eight patients (45.7%) showed improvement of menstrual cycle regularity after 3 months of metformin use, whereas 57 patients (54.3%) had no change. The mean free testosterone measured after 3 months of treatment was significantly lower in metformin responders than in non-responders. The other parameters did not differ between the groups. Of the 23 patients who used pioglitazone for 3 to 6 months, 19 patients (82.6%) showed improvement in their menstrual cycles.
CONCLUSION
Metformin treatment seems to be effective for the improvement of menstrual cyclicity irrespective of insulin resistance in women with PCOS. When metformin related adverse effect occurred, pioglitazone would be effective for aiding the resumption of the menstrual cycle.

Keyword

Polycystic ovary syndrome; Metformin; Pioglitazone

MeSH Terms

Female
Humans
Insulin
Insulin Resistance
Menstrual Cycle
Metabolome
Metformin
Ovulation
Periodicity
Polycystic Ovary Syndrome
Testosterone
Thiazolidinediones
Insulin
Metformin
Testosterone
Thiazolidinediones
Full Text Links
  • CERM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr